Sigyn Therapeutics (SIGY) Retained Earnings (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Retained Earnings of $11.5 million for Q3 2025, up 0.87% sequentially from $11.4 million in Q2 2025, and up 180.96% YoY from $4.1 million in Q3 2024.
Sigyn Therapeutics (SIGY) Retained Earnings (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Retained Earnings for 10 years, with the latest figure at $11.5 million in Q3 2025.
- Quarterly Retained Earnings rose 180.96% year-over-year to $11.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $11.5 million (up 180.96% YoY) and the FY2024 annual result came in at $10.2 million, up 28.95% from the prior year.
- Retained Earnings climbed to $11.5 million in Q3 2025 per SIGY's latest filing, from $11.4 million in the prior quarter.
- Over five years, Retained Earnings peaked at $11.5 million in Q3 2025 and troughed at -$15.4 million in Q1 2025.
- A 5-year average of -$2.4 million and a median of -$4.3 million in 2021 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings jumped 210.75% in 2023, then tumbled 315.01% in 2024.
- Over 5 years, Retained Earnings stood at -$4.3 million in 2021, then plunged by 68.68% to -$7.2 million in 2022, then surged by 210.19% to $7.9 million in 2023, then climbed by 28.95% to $10.2 million in 2024, then grew by 12.12% to $11.5 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered $11.5 million, $11.4 million, and -$15.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | -17.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 11.46 Mn |
| Jun 30, 2025 | 11.36 Mn |
| Mar 31, 2025 | -15.35 Mn |
| Dec 31, 2024 | 10.22 Mn |
| Sep 30, 2024 | -14.16 Mn |
| Jun 30, 2024 | -12.96 Mn |
| Mar 31, 2024 | -12.10 Mn |
| Dec 31, 2023 | 7.93 Mn |
| Sep 30, 2023 | 6.59 Mn |
| Jun 30, 2023 | 6.21 Mn |
| Mar 31, 2023 | -8.54 Mn |
| Dec 31, 2022 | -7.20 Mn |
| Sep 30, 2022 | -6.34 Mn |
| Jun 30, 2022 | -5.61 Mn |
| Mar 31, 2022 | -4.94 Mn |
| Dec 31, 2021 | -4.27 Mn |
| Sep 30, 2021 | -3.04 Mn |
| Jun 30, 2021 | -2.37 Mn |
| Mar 31, 2021 | -1.72 Mn |
| Dec 31, 2020 | -1.26 Mn |